1991 related articles for article (PubMed ID: 27190023)
1. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
2. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P
Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699
[TBL] [Abstract][Full Text] [Related]
3. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
4. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
5. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
[TBL] [Abstract][Full Text] [Related]
6. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
[TBL] [Abstract][Full Text] [Related]
7. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
[TBL] [Abstract][Full Text] [Related]
8. [
Coakeley S; Cho SS; Koshimori Y; Rusjan P; Ghadery C; Kim J; Lang AE; Houle S; Strafella AP
Brain Struct Funct; 2018 Mar; 223(2):589-595. PubMed ID: 28884232
[TBL] [Abstract][Full Text] [Related]
9. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
[TBL] [Abstract][Full Text] [Related]
10. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
11. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
12. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
[TBL] [Abstract][Full Text] [Related]
14. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
15. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
16. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
17. Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease.
Kim HK; Kim T; Baek MS; Kim EY; Sung YH; Lee JH; Ryu YH; Ahn SJ; Yoo HS; Lyoo CH
Eur J Neurol; 2023 Jun; 30(6):1639-1647. PubMed ID: 36915220
[TBL] [Abstract][Full Text] [Related]
18. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
[TBL] [Abstract][Full Text] [Related]
19. The utility of the combined use of
Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
[TBL] [Abstract][Full Text] [Related]
20. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
